Phase 4 N=63 Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Idiopathic Focal Segmental Glomerulosclerosis
Primary: Number of Participants With Adverse Events — 0; 11; 60 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Anemia, Sickle Cell
Primary: C-Reactive Protein — 11.4; 6.8 mg/l
Phase 2 N=60 Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Number of Subjects With Major Pathological Response (MPR) — 2; 16 Participants — p=0.0001
N/A N=101 Evaluation of Hyaluronic Acid Pulpotomies in Primary Molars
Pulpitis
Primary: Number of Teeth Sensitive to Percussion in 3 Groups — 7; 6; 3 teeth — p=>0.05
N/A N=180 Operative and Non-operative Treatment of Traumatic Arthrotomies
Traumatic Arthrotomy
Primary: Cost of Treatments — 1089; 11,973 USD
Phase 2 N=145 Evaluating Safety and Effectiveness of Octenidine Dihydrochloride
Preoperative Skin Preparation
Primary: Percentage of Abdominal Site Responder Rates at 10 Minutes — 79.2; 85.4; 52.6 percentage of abdomen sites
Phase 3 N=440 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma
Primary: Progression Free Survival (PFS) — 4.14; 3.15 Months — p=0.0184
N/A N=300 Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Androgenetic Alopecia · Coronavirus Disease 2019 · Covid19
Primary: Androgenetic Alopecia Frequency in Participants. — 209; 37; 11; 43 Participants
Phase 2 N=313 A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
Psoriasis
Primary: Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 — 25; 44; 41; 45 Participants — p=<0.0001
Phase 2 N=87 H-1337 Ophthalmic Solution Phase 1/2
Glaucoma, Open-Angle
Primary: Intraocular Pressure (IOP) — -4.45; -5.16; -4.93; -0.39 mm Hg
Phase 2 N=41 Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
Scar Prevention
Primary: Expert Panel Scar Assessment Score at Week 12: Part B — 37.8; 42.1 millimeter — p=0.168
Phase 2 N=18 MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness
Anxiety
Primary: Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint — -8.8; -23.5 score on a scale
Phase 2 N=13 A Pilot Study of Terazosin for Parkinson's Disease
Parkinson Disease
Primary: Incidence of Intervention-related Adverse Events Between Treatment Arms — 11; 4 Event
Phase 4 N=31 ProvodineTM Decreases Hand Contamination
Hand Hygiene
Primary: Control Period-Count the Number of Baseline Colony Forming Units Cultured From Anesthesiologist's Hands — 589.3 Colony forming units
N/A N=110 Probiotic VSL#3 for the Treatment of Gastrointestinal Symptoms Associated to Fibromyalgia
Fibromyalgia · Gastrointestinal Disease
Primary: Change, From Baseline to Endpoint (12 Weeks) in the Composite Score of Abdominal Pain, Abdominal Bloating and Metheorism Each One Measured in a 0-10 Visual Analog Scale…